Journal of Diabetes Investigation: Vol. 15, Issue 11 Summary
The November 2024 issue of the Journal of Diabetes Investigation brings together vital updates that span the emotional, social, clinical, and technological landscapes of diabetes care. This month's research emphasizes that successful diabetes management requires more than just clinical intervention; it demands a deep understanding of patient psychology, medication adherence, social disparities, and advanced personalized diagnostics.
Key Research Themes
- Fighting Social Stigma: Highlighting "The Ulaanbaatar Agreement" which aims to change diabetes terminology across Asia, shifting away from stigmatizing terms that reference "sugar" and "urine."
- Real-World Medication Adherence & Safety: A global meta-analysis reveals alarmingly low adherence rates to oral medications, while a massive Japanese study provides reassuring real-world safety data for the SGLT2 inhibitor tofogliflozin.
- Social and Aging Dynamics: Studies explore how income, employment, and age-related biomarkers influence clinical outcomes, showing how socio-economic status dictates the quality of care and risk of complications.
- Cutting-Edge Management: Highlighting the diagnostic and therapeutic power of Continuous Glucose Monitoring (CGM) in post-surgical complications and the use of machine learning to predict cardiovascular risk in kidney disease patients.
Takeaway for patients & families: Modern diabetes care is rapidly evolving to become more supportive and technologically advanced. From reducing social stigma to offering customized treatment paths based on your individual lifestyle and biomarkers, these findings pave the way for a more personalized and empathetic approach to health.
This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.
Haptoglobin Phenotype, Levels, and the Response to Fenofibrate in Type 2 Diabetes
Authors: Andrzej S. Januszewski, Hayden K. Young, Kwok‐Leung Ong, Liping Li, Rachel L. O’Connell, Timothy J. Lyons, etc.
Research Objective:
To evaluate how different haptoglobin (Hp)—a blood protein—phenotypes (Hp 1-1, Hp 2-1, and Hp 2-2) relate to Hp protein levels in the blood, and to assess how a lipid-lowering medication called fenofibrate affects these levels in people with type 2 diabetes.
Methods:
The researchers evaluated a sub-study of 480 adults with type 2 diabetes from the FIELD trial. They measured both the genetic Hp phenotype and Hp protein levels in blood plasma at baseline, after 6 weeks of fenofibrate therapy, and in a subset of 200 participants at 2 years post-randomization (comparing fenofibrate to placebo).
Main Findings:
Among the participants, the Hp phenotypes were distributed as follows: 15% had Hp 1-1, 49% had Hp 2-1, and 36% had Hp 2-2. Baseline haptoglobin levels differed significantly by genetic type. Treatment with fenofibrate for 6 weeks reduced Hp levels by a median of 21% across all groups. However, the reduction was noticeably smaller in individuals with the Hp 2-2 phenotype. After 2 years, levels returned to baseline in the placebo group but remained lowered in those taking fenofibrate.
Clinical Significance:
Because the Hp 2-2 phenotype is typically associated with a higher risk of heart and kidney complications in patients with diabetes, understanding that fenofibrate reduces haptoglobin levels—though to a lesser extent in this high-risk phenotype—helps explain how this medication works at a molecular level and may assist in tailoring targeted cardiovascular therapies.
Key points for patients:
Your genetic profile can influence how much of certain blood proteins you have and how well certain medications, like fenofibrate, work for you. While fenofibrate helped lower a potentially harmful protein in all participants, the effect varies depending on your specific genetic type.
https://doi.org/10.1111/jdi.14290
The Ulaanbaatar Agreement: Revising Diabetes Terminology in Asia to Combat Stigma
Authors: Yutaka Seino, Daisuke Yabe, Kazuhiro Tsumura, Chien‐Ning Huang, So Hun Kim, Weiping Jia, etc.
Research Objective:
To address and revise the medical terminology for diabetes in several Asian countries, which currently relies on words associated with "sugar" and "urine," creating unnecessary social stigma.
Methods:
During the 16th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD), a joint symposium was convened. Experts from various Asian countries and regions debated how local translations and historical terms impact the public perception of people living with diabetes.
Main Findings:
The symposium participants successfully reached a consensus on the urgent need to modify stigmatizing terms. While global terminology generally derives from "passing through," local translations in places like Japan, China, and South Korea have historically focused on "urine sugar," causing feelings of shame or embarrassment among patients. The committee agreed to outline plans and track terminology revisions at their next meeting in 2025.
Clinical Significance:
Language matters in healthcare. Changing the official medical terms to non-stigmatizing names can encourage more people to seek screening, speak openly about their condition, and adhere to their treatment plans without fear of social judgment.
Key points for patients:
Leading medical experts are working hard to change the name of diabetes in Asia. Eliminating labels that imply poor personal hygiene or excessive sugar consumption will help reduce the unfair embarrassment or shame sometimes felt by those living with the condition.
https://doi.org/10.1111/jdi.14330
Factors Influencing Severe Stroke (Cerebral Infarction) in Type 2 Diabetes
Authors: Takeshi Horii, Yoichi Oikawa, Kasumi Kidowaki, Akira Shimada, Kiyoshi Mihara
Research Objective:
To identify the factors that contribute to worsening stroke (specifically, atherothrombotic brain infarction) severity in patients with type 2 diabetes using a large national claims database in Japan.
Methods:
This was a retrospective, large-scale cross-sectional study. Researchers analyzed clinical data from 99,864 patients with type 2 diabetes who had experienced a stroke between 2008 and 2022. Severity at hospital discharge was evaluated using the modified Rankin scale (with a score of 3 or higher indicating severe disability).
Main Findings:
Severe stroke occurred in 44% of the patients. The odds of suffering a severe stroke increased by 1.69 times for every 10-year increase in age. Interestingly, having a body mass index (BMI) under 25 kg/m² was also linked to increased stroke severity. The analysis suggested that actively managing cholesterol and lipid levels using medications like statins and fibrates could be highly beneficial in reducing stroke severity.
Clinical Significance:
In people with type 2 diabetes, age and lower BMI can be indicators of vulnerability to more severe strokes. Initiating proactive treatment with lipid-lowering drugs (such as statins and fibrates) is key to protecting brain health and avoiding permanent disability.
Key points for patients:
Managing your cholesterol is just as important as managing your blood sugar. If you have type 2 diabetes, taking prescribed cholesterol-lowering medications can significantly decrease your chances of experiencing a disabling stroke as you age.
https://doi.org/10.1111/jdi.14284
How Income and Employment Influence Diabetes Care and Health in Japan
Authors: Takuya Yamaoka, Takehiro Sugiyama, Noriko Ihana‐Sugiyama, Akiko Kimura, Kouko Yamamoto, etc.
Research Objective:
To explore how a person's income and employment status are linked to their diabetes self-care habits, the types of treatments they receive, and their overall health outcomes.
Methods:
The researchers conducted a cross-sectional study linking health insurance claims data with a questionnaire survey of adults with diabetes (excluding type 1) living in Tsukuba City, Japan. They assessed patterns across different income levels and employment situations.
Main Findings:
Among the 264 participants, those in the higher-income bracket were much more likely to use advanced treatments like SGLT2 inhibitors or GLP-1 receptor agonists and attend annual health checkups regularly. Higher-income individuals also had a significantly lower risk of being hospitalized. Conversely, full-time workers reported better overall health but were less likely to exercise regularly compared to those who did not work.
Clinical Significance:
Social factors heavily impact a patient’s ability to manage diabetes. Health policy and clinical interventions should specifically target lower-income groups to ensure equitable access to modern therapies, and help busy full-time workers find realistic ways to incorporate physical activity into their routines.
Key points for patients:
Socio-economic factors like your job and income play a massive role in your health. If a busy schedule is keeping you from exercising, or if medication costs are preventing you from accessing newer treatments, make sure to discuss these challenges openly with your doctor.
https://doi.org/10.1111/jdi.14301
Predicting Aging-Related Health Risks in Elderly Patients with Diabetes
Authors: Kotaro Umamoto, Ryotaro Bouchi, Kotaro Soeda, Shosuke Satake, Tohru Hosoyama, etc.
Research Objective:
To determine if specific blood proteins (biomarkers) combined with physical mobility scores can help doctors predict future adverse health outcomes in older adults with diabetes.
Methods:
This retrospective study tracked 115 Japanese patients with diabetes aged 60 and older. The researchers monitored blood levels of age-related biomarkers (including adiponectin and GDF15) alongside the Barthel Index (which measures daily physical independence). They looked for correlations with severe events like emergency hospitalization, needing a higher level of nursing care, nursing home admission, or death.
Main Findings:
The study confirmed that monitoring GDF15, adiponectin, and the Barthel Index is highly effective. Together, these markers serve as powerful predictors for identifying which patients are at a higher risk of experiencing age-related adverse health events.
Clinical Significance:
By proactively checking these biological markers and assessing physical mobility, healthcare providers can identify vulnerable elderly patients early on, enabling personalized care modifications and supportive therapies to keep them living independently longer.
Key points for patients:
For seniors with diabetes, preserving physical independence is a primary goal. New blood tests measuring key aging proteins, alongside standard mobility evaluations, can help your healthcare team take preventive steps to keep you safe and healthy at home.
https://doi.org/10.1111/jdi.14286
Using Continuous Glucose Monitors to Manage Hypoglycemia After Stomach Surgery
Authors: Heejun Son, Bon Hyang Lee, Young Min Cho
Research Objective:
To demonstrate how Continuous Glucose Monitors (CGMs) can be used alongside medication to successfully diagnose and manage severe low blood sugar (hypoglycemia) that occasionally occurs after stomach-removal surgery (gastrectomy).
Methods:
The researchers evaluated three patients who experienced severe symptoms of low blood sugar after undergoing a gastrectomy. They monitored these patients for two weeks using a CGM. In the first week, patients maintained their normal lifestyle. In the second week, they were prescribed a medication called voglibose (0.2 mg) before each meal to slow down sugar absorption.
Main Findings:
The first-week CGM data confirmed multiple severe low blood sugar events occurring right after sharp, post-meal blood sugar spikes. In the second week, the use of voglibose significantly smoothed out these rapid spikes, drastically reducing both blood sugar variability and dangerous hypoglycemic events.
Clinical Significance:
Post-gastrectomy hypoglycemia can be difficult to catch using traditional finger-prick tests because the drops happen so fast. This study demonstrates that "theragnostic" CGM use (using the monitor to simultaneously diagnose the pattern and evaluate the treatment) is highly effective and safe for managing these patients.
Key points for patients:
If you have had stomach surgery and experience sudden dizziness, sweating, or shakiness after eating, you might be experiencing rapid drops in blood sugar. Wearing a Continuous Glucose Monitor can help your doctor visualize these drops and safely guide your treatment.
https://doi.org/10.1111/jdi.14299
Global Adherence to Oral Diabetes Medications is Alarmingly Low
Authors: Kansak Boonpattharatthiti, Pirune Na Songkla, Junpen Chantara, Chanchanok Koomsri, Ines Krass, etc.
Research Objective:
To determine the exact proportion of patients worldwide who consistently take their oral diabetes medications as prescribed.
Methods:
A systematic review and meta-analysis was performed on cross-sectional studies published globally between 2013 and 2023. The researchers looked only at high-quality studies assessing medication adherence with validated measures in at least 385 patients with type 2 diabetes.
Main Findings:
Analyzing 26 studies with a total of 69,366 patients, the overall estimated rate of adherence to oral antidiabetic drugs was just 55.53%. In a strict sensitivity analysis focusing only on the highest-quality studies, that number dropped even lower to 52.24%.
Clinical Significance:
This means that nearly half of all patients with type 2 diabetes globally do not take their oral pills as prescribed. This low adherence severely limits the effectiveness of diabetes care, highlighting the need for simpler drug regimens, patient support programs, and improved communication between doctors and patients.
Key points for patients:
You are not alone if you struggle to take your pills on time; nearly half of all people with diabetes share this difficulty. Always be honest with your healthcare provider if you find your pill routine hard to follow, as they can often adjust your regimen to make it easier.
https://doi.org/10.1111/jdi.14285
Real-World Safety and Efficacy of Tofogliflozin in Japanese Type 2 Diabetes Patients
Authors: Yuichiro Yamada, Daisuke Yabe, Kenichiro Shide, Atsushi Suzuki, Yasuo Terauchi, Yasunori Sato, etc.
Research Objective:
To evaluate the safety, side effects, and blood sugar lowering effects of tofogliflozin—an SGLT2 inhibitor—in everyday clinical settings across Japan.
Methods:
This large-scale, prospective observational study followed 11,480 participants with type 2 diabetes who had never used SGLT2 inhibitors. Doctors monitored patients across 1,103 Japanese medical institutions over a 104-week period.
Main Findings:
Over the course of two years, tofogliflozin successfully lowered HbA1c (a marker of long-term blood sugar control) by an average of 0.85% and resulted in an average weight loss of 3.05 kg. Side effects of special interest were quite low, with urinary and genital tract infections occurring in just 1.53% of participants, and dehydration in 1.25%. No unexpected safety concerns were found.
Clinical Significance:
SGLT2 inhibitors are highly favored for their cardiorenal protection and weight-loss benefits. This independent, non-commercial trial provides reassurance to doctors and patients that tofogliflozin is highly effective and safe for long-term real-world use.
Key points for patients:
Real-world data involving thousands of patients confirms that tofogliflozin safely controls blood sugar levels while helping to manage weight, with a very low risk of serious side effects.
https://doi.org/10.1111/jdi.14287
Machine Learning Predicts Heart Risks in Patients with Diabetic Kidney Disease
Authors: Ruihong Dai, Miaomiao Sun, Mei Lu, Lanhua Deng
Research Objective:
To develop an intelligent computer model that combines clinical patient data with specialized kidney imaging scans to predict which diabetic kidney disease (DKD) patients are at the highest risk of developing cardiovascular disease (CVD).
Methods:
This retrospective study analyzed 586 patients with DKD. Using shear-wave elastography (SWE)—an advanced ultrasound imaging technique that measures tissue stiffness—researchers extracted detailed imaging features. They combined these with standard clinical data to train multiple machine learning models to identify patients at risk of CVD.
Main Findings:
About 30.7% of the patients were found to be at risk for CVD. The Support Vector Machine (SVM) model, utilizing five major components (three clinical indicators and two SWE imaging features), outperformed all other prediction tools in identifying at-risk patients during validation testing.
Clinical Significance:
Cardiovascular disease is a leading cause of complication in people with diabetic kidney disease. Combining advanced non-invasive ultrasound findings with AI-powered analysis allows doctors to identify high-risk individuals early, potentially saving lives through timely preventative care.
Key points for patients:
New artificial intelligence tools are helping doctors spot cardiovascular risks earlier than ever. By analyzing kidney stiffness through specialized ultrasounds alongside regular blood work, doctors can customize your protection plan.
https://doi.org/10.1111/jdi.14294
